Finoriq research workspace
ADMA BIOLOGICS, INC. (ADMA) SEC Filings & Filing Highlights
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty. Review ADMA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Company
- ADMA BIOLOGICS, INC. (ADMA)
- Ticker
- ADMA
- Market Cap
- $2B
- Latest Price
- $8.79
- Industry
- Biotech & Pharma
ADMA BIOLOGICS, INC. (ADMA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ADMA BIOLOGICS, INC. (ADMA).
| Event | Form | Date |
|---|---|---|
| ADMA Biologics, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026. At the Annua...ADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Mee... | 8-K5.07 | 2026-06-02 |
| ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business UpdateADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-06 |
| ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Im...ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Immune Compromised Patients Two Years of Age a... | 8-K8.01 | 2026-05-04 |
| ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations...ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | 8-K7.01 | 2026-03-27 |
| ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a P...ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurch... | 8-K8.01 | 2026-03-02 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.